Chongsheng Pharmaceutical: Encouraging results from Phase II clinical trial of Angladivir granules.

Zhongsheng Pharmaceutical announced that the Phase II clinical trial of Angladavir granules developed independently by its holding subsidiary Zhongsheng Ruichuang for the treatment of 2-17-year-old patients with uncomplicated influenza A has recently obtained top-line analysis data. Preliminary results show that Angladavir granules demonstrated positive therapeutic effects and good safety in participants aged 2-17. The trial included a total of 72 participants, divided into three age groups, with high and low dosage groups in each age group. In this Phase II clinical trial, the median time for relief of flu symptoms was 31.72 hours, and the median time for fever relief was 24.07 hours. Stratified analysis showed similar times for flu symptom relief and fever relief among participants in different age groups. There were no severe adverse events, treatment-emergent adverse events leading to discontinuation, drug withdrawal, or trial withdrawal.